William Blair & Company

Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement

Retrieved on: 
Wednesday, November 29, 2023
Telephone, ATTN:, Verve, Sale, Jefferies Group, BMO Capital Markets, Attention, RBC Capital Markets, William Blair & Company, Eli Lilly and Company, Vesey Street, Floor, Prospectus, Madison Avenue, Cardiovascular disease, Guggenheim Partners, Equity capital markets, Security (finance), Exercise

All of the shares in the public offering are being sold by Verve.

Key Points: 
  • All of the shares in the public offering are being sold by Verve.
  • In addition, Verve has granted the underwriters a 30-day option to purchase up to 1,875,000 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.
  • The public offering and concurrent private placement are expected to close on December 1, 2023, subject to the satisfaction of customary closing conditions.
  • Jefferies, Guggenheim Securities, William Blair, BMO Capital Markets, and RBC Capital Markets are acting as joint book-running managers for the public offering.

Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

Retrieved on: 
Tuesday, November 28, 2023
Telephone, Lilly, ATTN:, Verve, Sale, Jefferies Group, BMO Capital Markets, Attention, Jefferies, RBC Capital Markets, William Blair & Company, Eli Lilly and Company, Vesey Street, Floor, Prospectus, Madison Avenue, Cardiovascular disease, Equity capital markets, Security (finance), Guggenheim Partners, Exercise

In addition, Verve expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • In addition, Verve expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering at the public offering price, less underwriting discounts and commissions.
  • The shares will be sold to Lilly at a price per share equal to the public offering price.
  • The proposed public offering and concurrent private placement are subject to market and other conditions, and there can be no assurance as to whether or when the public offering and concurrent private placement may be completed, or as to the actual size or terms of the public offering and concurrent private placement.
  • Jefferies, Guggenheim Securities, William Blair, BMO Capital Markets, and RBC Capital Markets are acting as joint book-running managers for the public offering.

Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company

Retrieved on: 
Monday, November 20, 2023
NPC, Sale, Physician, LLP, FDA, Form, Acquisition, Transaction, Disease, Therapy, William Blair & Company, Center of excellence, Business development, Syndrome, Pillsbury Winthrop Shaw Pittman, Prospectus, Niemann–Pick disease, Patient, Pharmaceutical industry

CELEBRATION, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the completion of its acquisition of Acer Therapeutics Inc. (Acer) which marks a significant step forward in executing Zevra’s strategy to become a leader in developing and commercializing treatments for rare diseases and furthers the Company’s commitment to supporting patient communities with limited or no existing therapeutic options. As previously announced on August 31, 2023, the capital-efficient transaction included approximately 2.96 million shares of Zevra stock and contingent value rights (CVRs) issued in exchange for all outstanding shares of Acer. The CVRs represent the right to receive up to $76 million payable upon the achievement of certain regulatory and net sales milestones, net of the amount payable, if any, to SWK Funding LLC, a former warrantholder of Acer. In addition, immediately prior to the signing and announcement of the merger agreement, Zevra purchased Acer’s senior secured debt for a combination of cash, Zevra stock and notes valued at $28.5 million as a condition of entering into the merger agreement with Acer.

Key Points: 
  • “Today’s acquisition marks an exciting milestone for Zevra as we advance our mission to deliver therapies to the rare disease community,” said Neil F. McFarlane, President and Chief Executive Officer of Zevra.
  • The acquisition brings complementary assets and bolsters Zevra’s commercial and development capabilities with the addition of key Acer personnel and existing commercial systems.
  • “Acer’s programs and capabilities are an excellent fit for Zevra, particularly OLPRUVA for UCDs, which is a serious rare genetic metabolic disorder.
  • Pillsbury Winthrop Shaw Pittman LLP served as legal advisor to Acer, and William Blair & Company, LLC served as exclusive financial advisor to Acer.

Augmedix Announces Pricing of Upsized Public Offering of 6,250,000 Shares of Common Stock

Retrieved on: 
Thursday, November 16, 2023
Sale, Research, William Blair & Company, Telephone, SAN, Attention, Security (finance), Form, Investment, Acceleration, Evercore, Public expenditure, Marketing, Prospectus, Equity capital markets, Life insurance, L.L.C

The offering was upsized from 5,500,000 shares of common stock.

Key Points: 
  • The offering was upsized from 5,500,000 shares of common stock.
  • The gross proceeds to Augmedix from this offering are expected to be $25 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Augmedix.
  • In addition, Augmedix granted the underwriters a 30-day option to purchase an additional 937,500 shares of its common stock.
  • All of the shares to be sold in the proposed offering will be sold by Augmedix.

Augmedix Announces Proposed Public Offering of 5,500,000 Shares of Common Stock

Retrieved on: 
Wednesday, November 15, 2023
Sale, Research, William Blair & Company, Telephone, SAN, Attention, Security (finance), Form, Investment, Acceleration, Evercore, Public expenditure, Marketing, Prospectus, Equity capital markets, Life insurance, L.L.C

SAN FRANCISCO, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Augmedix, Inc. (Nasdaq: AUGX) (“Augmedix”), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions, today announced that it has commenced an underwritten public offering of 5,500,000 shares of its common stock.

Key Points: 
  • SAN FRANCISCO, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Augmedix, Inc. (Nasdaq: AUGX) (“Augmedix”), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions, today announced that it has commenced an underwritten public offering of 5,500,000 shares of its common stock.
  • Augmedix intends to grant the underwriters a 30-day option to purchase an additional 15% of the shares of its common stock offered in the public offering.
  • All of the shares to be sold in the proposed offering will be sold by Augmedix.
  • A preliminary prospectus supplement and accompanying base prospectus relating to the offering and the shares of common stock being offered will be filed with the SEC.

TREND Health Partners Acquires Advent Health Partners

Retrieved on: 
Friday, December 15, 2023
Software, Professional Services, Payments, Technology, Hospitals, Artificial Intelligence, Health Technology, Health Insurance, Data Analytics, Practice Management, Finance, Health, Acquisition, William Blair & Company, LLP, DRG, Intelligence, Roger Hawkins (drummer), Barnes & Thornburg, Hospital, Holland & Knight, Management, Advent

TREND Health Partners (“TREND”), a rapidly growing provider of healthcare credit balance management and payment accuracy solutions, announced today that it has acquired Advent Health Partners, Inc. (“Advent”).

Key Points: 
  • TREND Health Partners (“TREND”), a rapidly growing provider of healthcare credit balance management and payment accuracy solutions, announced today that it has acquired Advent Health Partners, Inc. (“Advent”).
  • “Rarely do you come across two companies with such complementary capabilities and aligned visions as what we found with TREND and Advent.
  • We are very excited to welcome the Advent team into our organization,” said Sarah Armstrong, CEO of TREND.
  • OM Partners, LLC served as exclusive financial advisor and Barnes & Thornburg LLP served as legal counsel to Advent.

SharkNinja Announces Pricing of Secondary Offering of Ordinary Shares

Retrieved on: 
Wednesday, December 6, 2023
Consumer Electronics, Retail, Other Consumer, Consumer, Technology, Home Goods, Other Technology, Sale, NYSE, Madison Avenue, William Blair & Company, Telephone, Attention, Security (finance), J. P. Morgan, Jefferies, Varick Street, Morgan Stanley, CDH, Investment, 2nd Floor, Jefferies Group, Prospectus, Guggenheim Partners, Guggenheim, CDH Investments, SharkNinja, L.L.C

SharkNinja, Inc. (NYSE: SN), a global product design and technology company, today announced the pricing of the previously announced secondary offering of 6,095,169 ordinary shares of SharkNinja by certain selling shareholders affiliated with Xuning Wang and CDH Investments (collectively, the “Selling Shareholders”) at a price to the public of $47.00 per ordinary share.

Key Points: 
  • SharkNinja, Inc. (NYSE: SN), a global product design and technology company, today announced the pricing of the previously announced secondary offering of 6,095,169 ordinary shares of SharkNinja by certain selling shareholders affiliated with Xuning Wang and CDH Investments (collectively, the “Selling Shareholders”) at a price to the public of $47.00 per ordinary share.
  • The Selling Shareholder affiliated with CDH Investments has granted the underwriters a 30-day option to purchase up to an additional 914,275 ordinary shares of SharkNinja.
  • SharkNinja is not selling any ordinary shares in the offering and will not receive any of the proceeds from the sale.
  • Goldman Sachs & Co. LLC, J.P. Morgan, Jefferies and Morgan Stanley are acting as joint lead book-running managers for the offering.

SharkNinja Announces Launch of Secondary Offering of Ordinary Shares

Retrieved on: 
Monday, December 4, 2023
Other Consumer, Technology, Other Retail, Other Technology, Home Goods, Lifestyle, Consumer, Retail, Consumer Electronics, Sale, NYSE, Madison Avenue, William Blair & Company, Telephone, Attention, Security (finance), J. P. Morgan, Form, Jefferies, Varick Street, Morgan Stanley, CDH, Investment, 2nd Floor, Jefferies Group, SEC filing, Prospectus, Guggenheim Partners, Guggenheim, CDH Investments, SharkNinja, L.L.C

Additionally, the Selling Shareholder affiliated with CDH Investments intends to grant the underwriters a 30-day option to purchase up to an additional 841,896 ordinary shares of SharkNinja.

Key Points: 
  • Additionally, the Selling Shareholder affiliated with CDH Investments intends to grant the underwriters a 30-day option to purchase up to an additional 841,896 ordinary shares of SharkNinja.
  • SharkNinja is not selling any ordinary shares in the offering and will not receive any of the proceeds from the sale.
  • Goldman Sachs & Co. LLC, J.P. Morgan, Jefferies and Morgan Stanley are acting as joint lead book-running managers for the proposed offering.
  • The proposed offering of these securities will be made only by means of a prospectus.

Levine Leichtman Capital Partners Sells Therapeutic Research Center

Retrieved on: 
Tuesday, November 21, 2023
Finance, General Health, Health, Continuing, Professional Services, Education, Training, Other Health, Sale, Colibri Group, William Blair & Company, Kirkland & Ellis, Investment, Partner, Morgan Stanley, TRC, Partnership, Growth, Hospital, Pharmacotherapy

Levine Leichtman Capital Partners (“LLCP”), a Los Angeles-based private equity firm, announced today that it has sold its portfolio company Therapeutic Research Center (“TRC” or the “Company”) to Colibri Group, a portfolio company of Gridiron Capital.

Key Points: 
  • Levine Leichtman Capital Partners (“LLCP”), a Los Angeles-based private equity firm, announced today that it has sold its portfolio company Therapeutic Research Center (“TRC” or the “Company”) to Colibri Group, a portfolio company of Gridiron Capital.
  • TRC is a leading provider of independent, evidence-based continuing education and training for healthcare professionals and institutions with a particular content focus on drug therapy recommendations and medication management.
  • Over one million healthcare professionals and approaching four thousand hospitals rely on TRC’s advisory and education services to access concise, unbiased and timely information.
  • TRC was an investment of Levine Leichtman Capital Partners V, L.P.
    Morgan Stanley & Co. LLC served as the lead financial advisor to TRC, with support from William Blair & Company, LLC and Deloitte Corporate Finance LLC, and Kirkland & Ellis LLP served as legal counsel in connection with the sale.

Colibri Group Announces Strategic Acquisition of TRC Healthcare

Retrieved on: 
Monday, November 20, 2023
Pharmaceutical, Nursing, Health, Other Education, Continuing, Hospitals, Education, Training, Sale, Colibri Group, NETC, William Blair & Company, LLP, Kirkland & Ellis, Dentist, Pharmacy technician, Morgan Stanley, TRC, CE, Health care, Hospital, Pharmacy, Management, Financial adviser, Physician, Pharmacist, Colibri

Colibri Group (“Colibri”), a professional education company with leading brands that provide learning solutions to licensed professionals, announces today that the company has acquired TRC Healthcare.

Key Points: 
  • Colibri Group (“Colibri”), a professional education company with leading brands that provide learning solutions to licensed professionals, announces today that the company has acquired TRC Healthcare.
  • With the addition of TRC, Colibri Group adds leading capabilities for Pharmacists, Nurses, Physicians and other healthcare practitioners to its portfolio of professional education services.
  • At the same time, it enables us to deepen our solutions for healthcare clinicians, leaders, and institutions,” said Renee Altier, President of Healthcare at Colibri Group.
  • “We're thrilled to become part of Colibri Group," remarked Wes Crews, CEO of TRC Healthcare.